Edaravone
Edaravone, Radicava (edaravone) is a small molecule pharmaceutical. Edaravone was first approved as Radicava on 2017-05-05. It is used to treat amyotrophic lateral sclerosis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Edaravone, Radicava, Radicava ors
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Edaravone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RADICAVA | Mitsubishi Tanabe Pharma | N-209176 RX | 2017-05-05 | 2 products, RLD, RS |
| RADICAVA ORS | Mitsubishi Tanabe Pharma | N-215446 RX | 2022-05-12 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| edaravone | ANDA | 2024-12-02 |
| radicava | New Drug Application | 2021-12-06 |
| radicava radicava ors | New Drug Application | 2024-12-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| amyotrophic lateral sclerosis | EFO_0000253 | D000690 | G12.21 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
EDARAVONE, RADICAVA ORS, MITSUBISHI TANABE | |||
| 2025-05-12 | NP | ||
EDARAVONE, RADICAVA, MITSUBISHI TANABE | |||
| 2024-05-05 | ODE*, ODE-144 | ||
HCPCS
Code | Description |
|---|---|
| J1301 | Injection, edaravone, 1 mg |
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | — | 2 | — | 1 | — | 3 |
| Cerebral infarction | D002544 | — | I63 | — | 2 | — | 1 | — | 3 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 2 | — | 5 | — | 1 | 8 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | 2 | — | 5 | — | 1 | 8 |
| Sclerosis | D012598 | — | — | — | — | 5 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | — | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 2 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | — | 9 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 2 | — | — | — | — | 2 |
| Hepatic insufficiency | D048550 | — | — | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Edaravone |
| INN | edaravone |
| Description | Edaravone is a pyrazolone that is 2,4-dihydro-3H-pyrazol-3-one which is substituted at positions 2 and 5 by phenyl and methyl groups, respectively. It has a role as a radical scavenger and an antioxidant. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1=NN(c2ccccc2)C(=O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 89-25-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL290916 |
| ChEBI ID | 31530 |
| PubChem CID | 4021 |
| DrugBank | DB12243 |
| UNII ID | S798V6YJRP (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,451 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,744 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use